Consensus Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.92 ^USD	-0.11%		-15.61%	+12.06%

Apr. 24	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	MT
Apr. 24	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	MT

Evolution of the average Target Price on Centessa Pharmaceuticals plc

Price target over the last 5 years

History of analyst recommendation changes

23b4bc615.qOBaAezlmbdcpM0pFPW6lD3r5er2tZFjMcB1I3FSw_0.8I8Xbdy66sEw5aJcfI3lzgiB1oalh9gXQrIxZ1w4s7SYpyNS1a_6wi7AiA~909dbb2140eadf63700b054655844f1a

Analyst Recommendations on Centessa Pharmaceuticals plc

Morgan Stanley Upgrades Centessa Pharmaceuticals to Equalweight From Underweight, Doubles Price Target to $8 From $4 on 'Encouraging' Preclinical Data on Narcolepsy Treatment Candidate	23-10-26	MT
Guggenheim Adjusts Price Target on Centessa Pharmaceuticals to $10 From $9, Maintains Buy Rating	23-08-15	MT
Goldman Sachs Adjusts Price Target on Centessa Pharmaceuticals to $5 From $4.50, Maintains Neutral Rating	23-08-15	MT
BMO Capital Adjusts Centessa Pharmaceuticals Price Target to $15 From $11, Maintains Outperform Rating	23-07-25	MT
Evercore ISI Initiates Centessa Pharmaceuticals at Outperform Rating	23-06-21	MT
Guggenheim Initiates Centessa Pharmaceuticals at Buy With $9 Price Target	23-06-12	MT
SVB Securities Initiates Centessa Pharmaceuticals at Outperform With $6 Price Target	23-03-17	MT
Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $4 From $5, Maintains Underweight Rating	23-01-24	MT
Morgan Stanley Double Downgrades Centessa Pharmaceuticals to Underweight From Overweight, Adjusts Price Target to $5 From $10	22-08-12	MT
BMO Capital Adjusts Centessa Pharmaceuticals' Price Target to $11 from $19, Keeps Outperform Rating	22-08-11	MT
Goldman Sachs Adjusts Centessa Pharmaceuticals' Price Target to $4 From $5, Keeps Neutral Rating	22-08-11	MT
Morgan Stanley Adjusts Price Target for Centessa Pharmaceuticals to $10 From $15, Maintains Overweight Rating	22-07-14	MT
BMO Capital Starts Centessa Pharmaceuticals at Outperform With $19 Price Target	22-06-17	MT
Goldman Sachs Adjusts Centessa Pharmaceuticals' Price Target to $8 from $12, Keeps Neutral Rating	22-05-24	MT
Morgan Stanley Adjusts Centessa Pharmaceuticals Price Target to $15 From $19, Maintains Overweight Rating	22-05-24	MT
Morgan Stanley Trims Centessa Pharmaceuticals Price Target to $19 From $20, Maintains Overweight Rating	22-04-05	MT
Goldman Sachs Starts Centessa Pharmaceuticals at Neutral, Maintains Price Target at $12	22-02-11	MT
Morgan Stanley Adjusts Centessa Pharmaceuticals' Price Target to $20 from $37, Keeps Overweight Rating	22-02-01	MT
CENTESSA PHARMACEUTICALS : Jefferies Starts Centessa Pharmaceuticals at Buy With $35 Price Target	21-06-22	MT
CENTESSA PHARMACEUTICALS : Morgan Stanley Starts Centessa Pharmaceuticals at Overweight With $37 Price Target	21-06-22	MT
CENTESSA PHARMACEUTICALS : Goldman Sachs Starts Centessa Pharmaceuticals at Buy With $42 Price Target	21-06-22	MT